Abstract: Specific variants in genes that encode adipokines and their mRNA and protein expression were previously studied in type 2 diabetes mellitus (T2DM) and obesity, and similar studies have been performed for chronic periodontitis (CP). The aim of this case-control study was to investigate the possible impacts of adiponectin (ADIPOQ), leptin (LEP) and its receptor (LEPR), and resistin (RETN) on the etiopathogenesis of CP. Examinations were performed on 118 non-periodontitis healthy subjects (healthy controls, HC), 205 healthy individuals with CP (H + CP) and 86 type 2 diabetes patients with CP (T2DM + CP). Variants within the ADIPOQ (rs2241766, rs1501299), LEP (rs13228377, rs2167270), LEP receptor (rs1805096), and RETN (rs1862513) genes were determined by qPCR. In addition, the plasma levels of ADIPOQ, LEP, and RETN were analysed by ELISA for 80 individuals. The genotype frequencies of the SNP ADIPOQ +45G/T (rs2241766) differed between the HC and H + CP groups (p=0.03, p corr >0.05), and carriers of the TT genotype had a lower risk of developing CP compared to carriers of the GG or TG genotypes (p<0.01, p corr >0.05). However, there were no significant differences in the plasma levels of ADIPOQ, LEP or RETN between the study groups (p > 0.05). Plasma levels of the adipokines were also independent of the gene profiles (p > 0.05). Adipokine plasma levels did not change in patients with H + CP/T2DM + CP compared to HC, but we did identify a specific polymorphism in the ADIPOQ gene that was associated with CP. Although the ADIPOQ +45G/T (rs2241766) gene variant may be a candidate biomarker for CP, further research is required in larger populations with different ethnic backgrounds before any final conclusions can be drawn about the role of this gene in CP.
Introduction
Chronic periodontitis (CP) affects periodontal tissues and may lead to alveolar bone destruction and tooth loss. 1 A potential key step in the etiopathogenesis of this disease may be the invasion of the periodontium by periodontal pathogens and deceive host defences. 2 Additionally, there is a relationship between CP, type 2 diabetes mellitus (T2DM) and/or Declaration of Interests: The authors certify that they have no commercial or associative interest that represents a conflict of interest in connection with the manuscript. obesity, 3, 4 all of which are diseases associated with low-grade inflammation.
Adipocytes are the main producers of the pro-/ anti-inflammatory cytokines called adipokines. Recent studies suggest that adipokines (adiponectin, ADIPOQ; leptin, LEP; resistin, RETN) are also secreted by periodontal ligament (PDL) cells, and could be regulated by periodontal pathogens and inflammatory mediators. 5 As a result, adipokines are potential candidate molecules that could account for the association between CP, T2DM and/or obesity. 6 Two polymorphisms in the ADIPOQ gene have been studied in Japanese T2DM patients with CP. 7 In Indian population, a gene variant in the RETN gene has been associated with periodontal inflammation in both obese and non-obese patients. 8 To date, no study has analysed the variability in adipokine genes in Caucasian subjects with known periodontal statuses.
A recent meta-analysis 9 focused on adipokine profiles (ADIPOQ, LEP and RETN) as biomarkers in the gingival crevicular fluid (GCF) of obese and non-obese CP patients. Periodontitis mainly affected the circulating levels of ADIPOQ and RETN whereas obesity and periodontitis affected the circulating levels of LEP and favoured a pro-inflammatory state. 10 The meta-analysis by Zhu et al. 11 found elevated serum levels of LEP and decreased serum levels of ADIPOQ in periodontitis patients compared with controls that had a body mass index (BMI) <30. Similarly, decreased plasma levels of ADIPOQ were found in patients with severe periodontitis compared with patients with mild or moderate periodontitis, independent of overweight or obese status, 12 and the levels of LEP in the GCF and serum correlated with periodontal parameters. 13 Nevertheless, serum levels of LEP and ADIPOQ did not significantly change after periodontal treatment in systemically healthy individuals. 11 The review by Devanoorkar et al. 14 provides insight into the biological action of RETN and its potential role in periodontitis and DM. These pleiotropic adipokines may influence periodontal tissues via different mechanisms. ADIPOQ stimulates the expression of growth factors and extracellular matrix, in vitro wound healing, and proliferation. Furthermore, ADIPOQ enhances the activity of bioactive molecules, such as enamel matrix derivatives, which are critical for periodontal regeneration. 5 LEP enhances the expression of matrix metalloproteinases in human gingival fibroblasts and affects bone metabolism, which may contribute to the degradation of the collagen-rich extracellular matrix and the destruction of the alveolar bone. 15 A meta-analysis by Akram et al. 9 suggests that monocytes and macrophages that are present in chronic periodontal disease may be the major source of RETN following stimulation by pro-inflammatory cytokines in periodontal tissues.
The effects of specific variants in genes that encode adipokines on their mRNA/protein expression were previously studied with controversial results. Nevertheless, adipokines are considered to be involved in the etiopathogenesis of CP, and we hypothesize that an individual´s adipokine gene profile may predispose the patient to this multifactorial inflammatory disease.
The aims of this study were: i) to determine six common single nucleotide polymorphisms (SNPs) in the genes that encode ADIPOQ, LEP and its receptor (LEPR), and RETN, ii) to analyse adipokine plasma levels in subgroups of systemically healthy individuals with or without CP and individuals with both T2DM and CP to investigate the possible impacts of these adipokines on the etiopathogenesis of CP.
Methodology
The study was performed with the approval of the Committees for Ethics of the Medical Faculty, Masaryk University Brno (No. 13/2013) and the St. Anne´s Faculty Hospital. Written informed consent was obtained from all participants before inclusion in the study, in accordance with the Declaration of Helsinki.
Study population and clinical examinations
In this case-control (or case-case) association study, 409 individuals from the region of South Moravia were randomly selected. Participants were recruited from the patient pool of the Periodontology Department, Clinic of Stomatology, St. Anne's Faculty Hospital Brno, from 2010 to 2017. The inclusion criteria for this study were willingness to participate, compliance with the diagnostic criteria for CP and/or T2DM, and for the control group, systemic and periodontal health. No participants were receiving treatment for periodontitis at the time of diagnosis, but treatment was offered to all participants following diagnosis. Similar to the patients with CP, healthy controls were required to have at least 20 remaining teeth and be in good general health. For the DM patients, this criterion had to be relaxed because most DM patients who were willing to undergo a dental examination had significantly fewer teeth. As a result, we included all DM patients who had at least 12 of their own teeth for which the periodontal indexes could be examined so that a statistically evaluable size of the sample set could be reached. The exclusion criteria for this study were a history of systemic disease (such as coronary artery disease, malignancies, immunodeficiency disorders), current pregnancy or lactation, immunosuppression that was attributable to a medication or concurrent illness, use of antibiotics or anti-inflammatory drugs within six weeks of recruitment, and inability to consent.
The diagnosis of non-periodontitis/periodontitis was based on a detailed clinical examination, medical and dental history, tooth mobility and a radiographic assessment. Probing depth (PD) and clinical attachment loss (CAL) were measured using a UNC-15 periodontal probe at four sites for every tooth. We also investigated the plaque index (PI) according to Silness and Löe 16 and the gingival index (GI) according to Löe 17 , and the presence of plaque and inflammation of the gingiva were evaluated for four surfaces of each tooth (distal, vestibular, mesial, oral). The resulting values for these measurements were calculated as an arithmetic mean. All of the patients with CP fulfilled the diagnostic criteria according to their CAL levels as defined by the International Workshop for a Classification of Periodontal Diseases and Conditions for Chronic Periodontitis: 18 Among these patients, ≥ 30% of the teeth were affected (generalized CP) and their PD was ≥ 4 mm. The severity of periodontitis was classified according to the amount of CAL as slight (1-2 mm CAL), moderate (3-4 mm CAL) or severe (> 5 mm CAL). 19 Thus, healthy controls had a CAL of less than 1 mm with a PD of up to 3.5 mm (i.e., below 4 mm) without any bone resorption.
The diagnosis of T2DM was based on the presence of clinical symptoms (such as polyuria, polydipsia, and weight loss) and biochemical parameters (glycaemia, glycated haemoglobin, ketoacidosis, and autoantibody status) at the outpatient unit of the Diabetology Clinics in Brno. In accordance with the American Diabetes Association guidelines, 20 patients with typical symptoms were diagnosed upon finding glucose at >11.0 mmol/L in the absence of clinical manifestations, blood glucose in venous plasma that was ≥ 7.0 mmol/L after 8 h of fasting, blood glucose from venous plasma 2 h after consuming 75 g glucose (oral glucose tolerance test) that was > 11.0 mmol/L, or HbA1c ≥ 48 mmol/mol.
Genetic analysis
DNA for the genetic analysis was extracted from peripheral blood leukocytes using standard phenol/ chloroform procedures with proteinase K.
Candidate genes that encode adipokines and their specific genetic variants were selected based on previously described associations in other populations, 7, 8 their possible functional impacts on the etiopathogenesis of CP, a minor allele frequency (MAF) higher than 0.1 in the European Caucasian population studied and/or a localization that falls within the haplotype structure of the gene.
Six polymorphisms in total were analysed: ADIPOQ +276G/T (rs1501299), LEP 3´UTR A/G (rs13228377), LEP +19A/G (rs2167270), LEPR +384A/G, P1019P (rs1805096), and RETN -420C/G (rs1862513) were assayed by polymerase chain reaction (PCR) using 5′ nuclease TaqMan® assays (C___7497299_10, C___3001672_10, C__15966471_20, C___8722383_20, and C___1394112_10, respectively). Real-time PCR protocols were designed according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, USA), fluorescence was measured using the ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Carlsbad, USA) and the real-time and endpoint fluorescence data were analysed using the SDS version 1.2.3 software (Applied Biosystems, Carlsbad, USA).
Although the TaqMan® assay (C__26426077_10, Thermo Fisher Scientific, Waltham, MA, USA) was available for the last SNP (ADIPOQ +45G/T (rs2241766)), this assay was not used due to incorrect genotyping results in the positive control samples. Thus, PCR followed by digestion with a specific restriction enzyme (RFLP-PCR) was used. PCR was carried out in a volume of 13.0 µL containing 50 ng of genomic DNA, 0.75 µM of each primer (forward: 5´-GAGTCCTTTGTAGGTCCCAAC-3´, reverse: 5´-CTTTCTCCCTGTGTCTAGGC-3´) as previously designed Ukkola et al., 21 1 U of Taq DNA polymerase (Thermo Fisher Scientific, Waltham, USA), 3.8 mM of MgCl 2 , 10x MgCl 2 -free reaction buffer with (NH 4 ) 2 SO 4 (Thermo Fisher Scientific, Waltham, MA, USA) and 0.6 mM of deoxyribonucleoside triphosphate mix (Thermo Fisher Scientific, Waltham, USA). The reaction was carried out in a Sensoquest labcycler (Schoeller, Germany). The first step of the PCR was denaturation for 10 min at 95°C followed by 14 cycles of 95°C for 20 s, 64°C for 30 s and 72°C for 30 s, then 20 cycles of 95°C for 30 s, 50°C for 30 s and 72°C for 30 s. The last synthesis step was extended to 5 min at 72°C. The PCR product was then incubated with the restriction enzyme SmaI (TaKaRa, Kusatsu Shiga, Japan) according to the manufacturer's instructions. The fragments were then visualized using 3.0% agarose gel electrophoresis (constant strain 90 V) with ethidium bromide. The size of the products was determined using a 50 bp ladder (Thermo Fisher Scientific, Waltham, USA). The lengths of the fragments after digestion were 272 + 128 bp (GG), 400 + 272 + 128 bp (GT) and 400 bp (TT).
Plasma levels analysis
Plasma levels of ADIPOQ, LEP and RETN were measured in a subgroup of 80 individuals. The plasma samples were prepared from venous blood collected in a tube containing 0.5 M EDTA, separated by centrifugation (465 g, 4°C, 10 min), and then stored at −70°C within 30 min after collection.
Adipokine plasma levels were determined using enzyme-linked immunosorbent assay (ELISA) kits: Adiponectin Human ELISA, High Sensitivity (Sandwich) RD191023100 (BioVendor Laboratory Medicine, Brno, Czech Republic), Leptin ELISA DEE007 (Demeditec Diagnostics GmbH, Kiel, Germany) and Human Resistin ELISA Kit ER1001-1 (Assaypro, St. Charles, USA), with VersaMax™ ELISA Microplate Reader (Molecular Devices, Sunnyvale, USA) according to the manufacturer's instructions.
Statistical analysis
The sample size of the study was statistically assessed using both a standard power calculation and a calculation of error margins for the estimates of a binomial response distribution. Due to the wide range of relative frequencies that was expected in the possible outcome response rates, the calculation of the 95% confidence margin of errors for the point estimates used 50% as the greatest demand for the sample size reference value. 22 Assuming this, the sample size for all three cohorts (HC=non-periodontitis healthy controls, H+CP=healthy individuals with chronic periodontitis, T2DM+CP=type 2 diabetes patients with chronic periodontitis) enabled point estimates of the relative frequencies with 95% error margins that were less than 11% (HC: < 9.0%; H + CP: < 6.8%; T2DM + CP: < 10.5%). The power analysis was focused on the comparisons performed by the Fisher's exact test assuming standard settings for the probability measures, i.e., an alpha level < 0.05 and power = 0.80. As a result, statistical comparisons between the HC and H + CP cohorts maintain a detectable effect size of +/-12%, and comparisons between the H + CP and T2DM + CP cohorts reach a detectable effect size of +/-17%. Both calculations assumed a 50% genotype occurrence rate as a reference value. Analyses were performed using PASS 13 software (NCSS, LLC, Kaysville, USA).
Standard descriptive statistics were applied in the analysis and are shown as the mean with standard deviations (SD) or the median with quartiles for quantitative variables and absolute or relative frequencies for categorical variables. One-way analysis of variance (ANOVA) or Kruskal-Wallis ANOVA were performed to compare the continuous variables among the groups. The allele frequencies were calculated from the observed numbers of genotypes. Based on the known functional relevance of the SNPs ADIPOQ +45G/T (rs2241766) and + 276G/T (rs1501299), Kaklamani et 
Results
The study group was comprised of 118 HC, 205 H + CP and 86 T2DM + CP patients. No patients with T2DM and healthy periodontal tissue were included in this study, and as a result, comparisons of the selected parameters were made between the H + CP or T2DM + CP vs. HC groups (case-control study) and the H + CP vs. T2DM + CP groups (case-case study).
Power calculations were performed separately for the mutual comparisons of different study cohorts and determined that the recruited sample size was sufficient for a confident estimation of the genotype and haplogenotype occurrence rates (95% error margins: HC < 9.0%, H + CP < 6.8% and T2DM + CP < 10.5%). Compared to the statistically detectable effect size (assuming 80% power of the Fisher exact test with an alpha level of < 0.05) the statistically non-significant differences between the compared groups (HC vs. H + CP, H+CP vs. T2DM + CP) were remarkably lower than the predicted detectable effects. The results of these tests are therefore consistent with the statistical power of the study.
Clinical analysis
While gender proportions were balanced in all study groups, the mean age differed between H + CP/T2DM + CP patients and HC (p < 0.01/p < 0.05, respectively); demographic data are given in Table 1 . T2DM patients suffered from the disease for an average of 9.4 ± 7.0 years (standard deviation, SD). BMI was highest in the group of T2DM + CP patients, with a median value that was between overweight and obesity ( 
Genetic analysis
All of the studied polymorphisms were in HWE in the control group (p > 0.05). Carriers of the TT genotype vs. carriers of the GG + TG genotypes for the SNP ADIPOQ Allele and genotype frequencies for the investigated SNPs in ADIPOQ +276G/T (rs1501299), LEP 3´UTR A/G (rs13228377), LEP +19A/G (rs2167270), LEPR +384A/G, P1019P (rs1805096), and RETN -420C/G (rs1862513) were not significantly different between the study groups (p > 0.05; Table 2 ).
Plasma levels analysis
Adipokine plasma levels were measured in 23 HC, 20 H + CP patients and 37 T2DM + CP patients. No significant differences in plasma levels of ADIPOQ, LEP or RETN were found between the different study groups (Figure 1 and 2) .
In addition, adipokine plasma levels were evaluated according to BMI. Although there were no differences in the plasma levels of ADIPOQ and RETN between the normal weight (n = 16, BMI < 25 kg/m 2 ), overweight (n = 27, 25 ≤ BMI < 30 kg/m 2 ) and obesity (n = 37, BMI ≥ 30 kg/m 2 ) subgroups, the median LEP plasma levels were higher in the obese patients (19.6 [12.0-33.4] ng/mL) compared with the overweight (8.5 [5.6-15.6] ng/mL) and normal weight individuals (1.9 [0.4-9.1] ng/mL, p < 0.05, p corr > 0.05, p < 0.01, p corr > 0.05, Figure 3) . Thus, the median of the LEP/ADIPOQ ratio was highest in the subgroup of obese patients (p < 0.01, p corr > 0.05, Figure 4 ). In the BMI < 25 kg/m 2 subgroup, the Table 3 ). Nevertheless, lower levels of low density lipoprotein (LDL) were found in the carriers of the TT genotype of the SNP ADIPOQ +45G/T (rs2241766) than in other groups (p < 0.05), especially in the subgroup of T2DM patients (p < 0.01, p corr > 0.05, data not shown).
Discussion
Although the link between CP, T2DM and/or obesity is not fully understood, 4 adipokines could represent a mechanism that influences the impact of periodontitis on systemic diseases. 24 A review by Ogawa et al. 25 described the role of the major adipokines and their associations with the pathogenesis of periodontitis in T2DM. Obesity may also modulate the systemic and periodontal levels of adipokines in favour of a pro-inflammatory state that is independent of periodontal therapy. 26 ADIPOQ is a cellular hormone that plays a role in controlling the homeostasis of glucose, energy and lipid metabolism and is a key regulator of the innate immune system. 27 Chronic low-grade inflammation and oxidative stress during obesity have been shown to downregulate ADIPOQ gene and protein expression. 28 Moreover, an LEP/ADIPOQ imbalance may be an important marker for an elevated risk of developing abdominal obesity. 29 LEP, which is an obesity-regulatory hormone, is encoded by the LEP gene ("obese" gene). LEP interacts with LEPR, which leads to the regulation of appetite, control of the body's energy expenditure and maintenance of bone mass and can reduce adipose tissue inflammation. LEP has a regulatory role in the interplay between energy metabolism and the immune system and is a cornerstone in the new field of immunometabolism. Therefore, Pérez-Pérez et al. 30 suggested that LEP and LEPR should be considered as markers of inflammation and immune activation in the intersection of the innate-adaptive systems and as possible targets for intervention. A study by Nokhbehsaim et al. 31 demonstrated that LEP negatively interferes with the regenerative capacity of PDL cells, which suggests that LEP has a pathomechanistic link between obesity and compromised periodontal healing. A previous study also found significantly elevated levels of LEP in the plasma of patients with aggressive periodontitis compared with non-periodontitis individuals in a Chinese population. 32 In humans, RETN is predominantly secreted by macrophages rather than by adipocytes. 33 RETN plays a role as a mediator of insulin resistance and modulates inflammation in chronic periodontal disease. Increased serum levels of RETN were found with periodontal inflammation, which indicates a potential inflammatory role in periodontitis. 8 Increased RETN serum levels were also significantly associated with periodontal condition and there was also a trend towards decreased levels of ADIPOQ in subjects with periodontitis in a Japanese population. 34 Saito et al. 35 concluded that increased RETN serum levels in middle-aged Japanese women with periodontitis may affect their systemic health. RETN levels in patients with CP and systemic inflammatory disorders, such as diabetes, obesity, or rheumatoid arthritis, were not significantly higher than the levels in patients diagnosed with CP alone. 36 Similar to the studies by Sete et al. 37 and Mendoza-Azpur et al., 38 this study found no significant differences in the circulating levels of ADIPOQ, LEP or RETN between the CP and HC groups. Furthermore, higher median LEP plasma levels were found among participants with normal weight in the T2DM + CP group when compared to the H + CP group (though this difference was not significant after correction for multiple comparisons), which corresponds to the differences in the median LEP/ADIPOQ ratio found between these patients. It appears that diabetes status may affect the levels of these adipokines independent of weight.
Regardless of periodontal status, LEP plasma levels were significantly higher in obese patients than in the overweight or normal weight individuals, and thus the median of the LEP/ADIPOQ ratio was highest in the subgroup of obese patients in our study. These findings are in line with the results presented by López-Jaramillo et al., 39 however, they must be interpreted with caution due to the number of subjects included in these comparisons.
The SNP ADIPOQ +45C/T (rs2241766) that is located in exon 2 results in a synonymous Gly15Gly change and is relatively close to exon-intron boundary. 40 Thus, this polymorphism may affect splicing and modify the expression of the gene. 41 In the study by Yang et al., 42 the mRNA levels of the G allele were consistently higher than those of the T allele in omental adipose tissue. Nevertheless, the mean plasma levels of ADIPOQ were similar between individuals with different ADIPOQ +45C/T (rs2241766) genotypes. 40 In line with this result, no significant association was found between ADIPOQ plasma levels and ADIPOQ +45C/T (rs2241766) gene variants. Furthermore, we found that plasma levels of ADIPOQ were similar between carriers of different haplogenotypes that consisted of the SNPs ADIPOQ +45C/T (rs2241766) and +276C/T (rs1501299). In contrast, Jang et al. 43 previously suggested that subjects carrying the TG haplotype ADIPOQ +45C/T (rs2241766) and +276C/T (rs1501299) had significantly lower levels of circulating ADIPOQ compared with non-TG carriers in both normal weight and overweight-obese individuals. We conclude that the possible association between the SNP ADIPOQ +45C/T (rs2241766) and CP may be a consequence of linkage between this polymorphism and another functionally consequential gene variant. It is not clear why there were no differences in the frequencies of the SNP ADIPOQ +45C/T (rs2241766) between the HC and T2DM groups and/or the H + CP and T2DM groups. One possibility is that patients with T2DM are not likely to be genetically predisposed to CP by a gene variant linked to the SNP ADIPOQ +45C/T (rs2241766) as they can develop CP as a consequence of hyperglycaemia or other pathophysiological mechanisms that are separate from adipokines.
Our results are in contrast to both of the previous studies that focused on ADIPOQ and RET N gene variability in patients with CP and T2DM/ obesity. 7, 8 These divergent results may be caused by inter-individual variability between populations. For instance, the ADIPOQ +45C/T (rs2241766) minor allele frequency (MAF, G allele) in the Czech population was 8.4%, while the MAF recorded in the study of a Japanese population was 31.4%; 7 both results are in line with frequencies reported for European or East Asian populations in the NCBI SNP database (https://www.ncbi.nlm.nih.gov/projects/SNP/ snp_ref.cgi?rs=2241766). The second reason for the discrepancies between these studies may be the small number of subjects enrolled, especially in the patient group. Only 43 patients with T2DM and CP were selected in the preliminary study of a Japanese population 7 and the RETN gene variant was only analysed in 90 participants that were then divided into three subgroups (non-obese non-periodontitis, non-obese periodontitis, obese periodontitis) from the Indian population, 8 which may limit the statistical power of these studies.
The main limitation of our study is that the subgroup of T2DM patients without periodontal disease could not be included as all of the diabetes patients suffered from different severities of periodontitis. However, while the size of our cohort (n = 409) was relatively small, it was still several times larger than the study populations of the two previous studies that investigated individual adipokine gene variability in patients with known periodontal status (43 Japanese patients/90 Indian participants). 7, 8 Unfortunately, we could only analyse plasma levels of the three adipokines, and did not measure salivary/GCF adipokine levels in our patients. Importantly, our study is the first to explore this issue in a Caucasian population, and we can claim a high degree of homogeneity in the study population because the participants were collected from a pool of patients of Czech-Caucasian descent from South Moravia.
Conclusions
The association of ADIPOQ and the LEP/ADIPOQ ratio with T2DM and CP was not statistically significant, and the plasma levels of all of the studied adipokines (ADIPOQ, LEP, and RETN) were independent of genetic profiles. Nevertheless, the TT genotype of the SNP ADIPOQ +45C/T (rs2241766) was associated with a lower risk of developing CP. Linkage analysis of this SNP with other gene variants in ADIPOQ and their subsequent functional characterization and effects on gene expression should be further investigated. We suggest that the use of larger study populations across different ethnic background is required to clarify the association between adipokine polymorphisms, adipokine levels and their impact on disease.
